TNIP3 and metabolic dysfunction-associated steatohepatitis: In recent studies, Liu et al.57 confirmed that adenovirus-mediated TNIP3 expression in the liver blocked NASH progression in mice, indicating that TNIP3 may be a promising therapeutic target for NASH.